Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
monarchE: Abemaciclib plus standard adjuvant endocrine therapy vs endocrine therapy alone in high‑risk HR+, HER2‑ early breast cancer (Japan cohort)
jRCT2080223612Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Started Aug 2017; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223612.